首页 > 最新文献

Translational Oncology最新文献

英文 中文
Single‑cell mapping of neutrophil extracellular trap signatures in lung adenocarcinoma reveals immune landscapes, prognostic potential, and therapeutic targets 肺腺癌中性粒细胞胞外陷阱特征的单细胞定位揭示了免疫景观、预后潜力和治疗靶点。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102651
Jingjie Liu , Kang Tian , Hui Shen , Lei Zhou , Subo Dong , Fuchun Huo , Jian Zhang
Neutrophil extracellular traps (NETs) have emerged as key modulators in the tumor microenvironment, yet their cellular heterogeneity, molecular mechanisms, and clinical relevance in lung adenocarcinoma (LUAD) remain elusive. Here, we performed an integrative single‑cell and multi‑omics dissection of NETs activity across LUAD tissues. Single‑cell transcriptomics revealed that NETs signatures were predominantly enriched in neutrophils but also detectable in dendritic cells and macrophages, where NETs‑high subpopulations exhibited intensified intercellular signaling. Genomic profiling indicated that NETs‑related genes were largely affected by missense mutations and single nucleotide polymorphisms (C > A and C > T), with frequent alterations in PTPRD, VCAN, and ZNF804A. Functional enrichment associated these genes with immune regulation and tumor‑promoting pathways. By integrating seven independent clinical cohorts, we constructed a machine‑learning–based NETs‑related prognostic signature (NETs‑Sig) that robustly predicted overall survival across datasets (AUC > 0.75). Patients with high NETs‑Sig scores exhibited immune‑cold phenotypes characterized by reduced immune infiltration and impaired antigen presentation, whereas low‑score cases displayed elevated MHC‑II expression, enhanced antigen processing, and putative sensitivity to immunotherapy. Experimental validation further identified AP2S1 as a central NETs‑Sig gene—overexpressed in multiple cancers and functionally promoting invasion and metastasis in LUAD cells. Together, our study delineates the cellular, genomic, and immunological frameworks of NETs in LUAD, establishes NETs‑Sig as a clinically actionable biomarker for risk stratification and immunotherapy guidance, and highlights AP2S1 as a promising therapeutic target for translational intervention.
中性粒细胞胞外陷阱(NETs)已成为肿瘤微环境中的关键调节剂,但其细胞异质性、分子机制和与肺腺癌(LUAD)的临床相关性仍不明确。在这里,我们对LUAD组织中的NETs活性进行了单细胞和多组学的综合解剖。单细胞转录组学显示,NETs特征主要富集在中性粒细胞中,但也可在树突状细胞和巨噬细胞中检测到,其中NETs高亚群表现出强化的细胞间信号传导。基因组分析表明,NETs相关基因在很大程度上受到错义突变和单核苷酸多态性(C > A和C > T)的影响,PTPRD、VCAN和ZNF804A基因频繁改变。功能富集将这些基因与免疫调节和肿瘤促进途径联系起来。通过整合七个独立的临床队列,我们构建了一个基于机器学习的NETs相关预后特征(NETs - Sig),该特征可靠地预测了各数据集的总生存期(AUC > 0.75)。NETs - Sig得分高的患者表现出免疫冷表型,其特征是免疫浸润减少和抗原呈递受损,而得分低的患者表现出MHC - II表达升高、抗原加工增强以及对免疫治疗的推定敏感性。实验验证进一步确定AP2S1是多种癌症中过表达的中心NETs - Sig基因,并在功能上促进LUAD细胞的侵袭和转移。总之,我们的研究描述了LUAD中NETs的细胞、基因组和免疫学框架,确立了NETs - Sig作为临床可操作的风险分层和免疫治疗指导的生物标志物,并强调了AP2S1作为翻译干预的有希望的治疗靶点。
{"title":"Single‑cell mapping of neutrophil extracellular trap signatures in lung adenocarcinoma reveals immune landscapes, prognostic potential, and therapeutic targets","authors":"Jingjie Liu ,&nbsp;Kang Tian ,&nbsp;Hui Shen ,&nbsp;Lei Zhou ,&nbsp;Subo Dong ,&nbsp;Fuchun Huo ,&nbsp;Jian Zhang","doi":"10.1016/j.tranon.2025.102651","DOIUrl":"10.1016/j.tranon.2025.102651","url":null,"abstract":"<div><div>Neutrophil extracellular traps (NETs) have emerged as key modulators in the tumor microenvironment, yet their cellular heterogeneity, molecular mechanisms, and clinical relevance in lung adenocarcinoma (LUAD) remain elusive. Here, we performed an integrative single‑cell and multi‑omics dissection of NETs activity across LUAD tissues. Single‑cell transcriptomics revealed that NETs signatures were predominantly enriched in neutrophils but also detectable in dendritic cells and macrophages, where NETs‑high subpopulations exhibited intensified intercellular signaling. Genomic profiling indicated that NETs‑related genes were largely affected by missense mutations and single nucleotide polymorphisms (C &gt; A and C &gt; T), with frequent alterations in PTPRD, VCAN, and ZNF804A. Functional enrichment associated these genes with immune regulation and tumor‑promoting pathways. By integrating seven independent clinical cohorts, we constructed a machine‑learning–based NETs‑related prognostic signature (NETs‑Sig) that robustly predicted overall survival across datasets (AUC &gt; 0.75). Patients with high NETs‑Sig scores exhibited immune‑cold phenotypes characterized by reduced immune infiltration and impaired antigen presentation, whereas low‑score cases displayed elevated MHC‑II expression, enhanced antigen processing, and putative sensitivity to immunotherapy. Experimental validation further identified AP2S1 as a central NETs‑Sig gene—overexpressed in multiple cancers and functionally promoting invasion and metastasis in LUAD cells. Together, our study delineates the cellular, genomic, and immunological frameworks of NETs in LUAD, establishes NETs‑Sig as a clinically actionable biomarker for risk stratification and immunotherapy guidance, and highlights AP2S1 as a promising therapeutic target for translational intervention.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102651"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated spatial and single-cell transcriptomics reveals RPL8 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma 综合空间和单细胞转录组学显示RPL8是肝细胞癌的预后生物标志物和治疗靶点。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102663
Jinna Tan , Junzhu Liang , Yaoyang Li , Jiaqian He , Hui Yin , Hemeng Wu , Yuzhen Luo , Mingfen Li , Fuli Long , Hongsheng Lin

Background & aims

Ribosomal protein L8 (RPL8) is up-regulated in hepatocellular carcinoma (HCC), yet its clinical value and microenvironment role remain unclear.

Methods

Multi-omics (TCGA, CPTAC), scRNA-seq (GSE146115) and spatial transcriptomics were integrated; function was tested by RPL8 knockdown, proliferation/migration assays and drug-sensitivity screens.

Results

RPL8 mRNA/protein were markedly elevated (p < 0.001) with AUC 0.95 for diagnosis. High RPL8 independently predicted shorter overall (HR 1.42) and disease-specific survival (HR 1.35). Mechanistically, RPL8 co-activated MYC/G2M signaling, rewired glutathione metabolism and correlated with cell-cycle/DNA-repair scores (p < 0.001). scRNA-seq showed selective RPL8 enrichment in malignant hepatocytes and exhausted CD8+ T cells; spatial maps revealed tumor-confined expression inversely linked to immune infiltration (p < 0.01). Silencing RPL8 suppressed proliferation, migration and glutathione synthesis (p < 0.001), while sensitizing cells to sirolimus and sclareol (p < 0.05).

Conclusions

RPL8 drives HCC progression and immune evasion, qualifying it as a diagnostic biomarker and therapeutic target.
背景与目的:核糖体蛋白L8 (RPL8)在肝细胞癌(HCC)中表达上调,但其临床价值和微环境作用尚不清楚。方法:整合多组学(TCGA、CPTAC)、scRNA-seq (GSE146115)和空间转录组学;通过RPL8敲除、增殖/迁移试验和药敏筛选检测功能。结果:RPL8 mRNA/蛋白显著升高(p < 0.001),诊断AUC为0.95。高RPL8独立预测较短的总生存率(HR 1.42)和疾病特异性生存率(HR 1.35)。在机制上,RPL8共同激活MYC/G2M信号,重新连接谷胱甘肽代谢,并与细胞周期/ dna修复评分相关(p < 0.001)。scRNA-seq显示,RPL8在恶性肝细胞和耗尽CD8+T细胞中选择性富集;空间图显示肿瘤受限表达与免疫浸润呈负相关(p < 0.01)。沉默RPL8抑制细胞增殖、迁移和谷胱甘肽合成(p < 0.001),同时使细胞对西罗莫司和巩膜醇敏感(p < 0.05)。结论:RPL8驱动HCC进展和免疫逃避,使其成为一种诊断生物标志物和治疗靶点。
{"title":"Integrated spatial and single-cell transcriptomics reveals RPL8 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma","authors":"Jinna Tan ,&nbsp;Junzhu Liang ,&nbsp;Yaoyang Li ,&nbsp;Jiaqian He ,&nbsp;Hui Yin ,&nbsp;Hemeng Wu ,&nbsp;Yuzhen Luo ,&nbsp;Mingfen Li ,&nbsp;Fuli Long ,&nbsp;Hongsheng Lin","doi":"10.1016/j.tranon.2025.102663","DOIUrl":"10.1016/j.tranon.2025.102663","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Ribosomal protein L8 (RPL8) is up-regulated in hepatocellular carcinoma (HCC), yet its clinical value and microenvironment role remain unclear.</div></div><div><h3>Methods</h3><div>Multi-omics (TCGA, CPTAC), scRNA-seq (GSE146115) and spatial transcriptomics were integrated; function was tested by RPL8 knockdown, proliferation/migration assays and drug-sensitivity screens.</div></div><div><h3>Results</h3><div>RPL8 mRNA/protein were markedly elevated (<em>p</em> &lt; 0.001) with AUC 0.95 for diagnosis. High RPL8 independently predicted shorter overall (HR 1.42) and disease-specific survival (HR 1.35). Mechanistically, RPL8 co-activated MYC/G2M signaling, rewired glutathione metabolism and correlated with cell-cycle/DNA-repair scores (<em>p</em> &lt; 0.001). scRNA-seq showed selective RPL8 enrichment in malignant hepatocytes and exhausted CD8<sup>+</sup> <em>T</em> cells; spatial maps revealed tumor-confined expression inversely linked to immune infiltration (<em>p</em> &lt; 0.01). Silencing RPL8 suppressed proliferation, migration and glutathione synthesis (<em>p</em> &lt; 0.001), while sensitizing cells to sirolimus and sclareol (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>RPL8 drives HCC progression and immune evasion, qualifying it as a diagnostic biomarker and therapeutic target.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102663"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma 一个血清衍生的三维肿瘤模型平台,用于个性化预测和监测胰腺导管腺癌的化疗反应。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102659
Sara Cherradi , Salomé Roux , Marie Dupuy , Eric Assenat , Hong Tuan Duong
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer, largely due to late diagnosis, tumor heterogeneity, and a dense, immunosuppressive stroma that limits therapeutic efficacy. While regimens like FOLFIRINOX and gemcitabine-based therapies offer some benefit, treatment selection remains empirical, with no reliable predictive models to guide personalized decisions. We adapted our previously validated serum-derived educated spheroid technology creating 3D spheroids using PDAC patient serum. These spheroids maintained structural integrity, viability, and consistent size over eight days, avoiding overgrowth. They also exhibited extracellular matrix deposition such as type I collagen, and expressed key genes involved in drug resistance and tumor progression including COL1A1, FN1, MMP2, CXCL1, and CXCL2. Using the Target-Independent Cell Killing (TICK) strategy, we established individualized chemograms to assess true therapeutic response helping clinicians in refining the optimal treatment protocol. In a 16-case study, our model achieved high concordance with clinical responses across gemcitabine, Gem-Pac, and FOLFIRINOX treatments supporting its utility in personalized care. Finally, we demonstrated that predictive accuracy was highest when patient serum was collected within a short window prior to treatment initiation. These findings support PDAC patient serum-educated spheroids as a rapid, non-invasive, and physiologically relevant tool for guiding personalized chemotherapy and monitoring treatment response in real time.
胰腺导管腺癌(PDAC)仍然是一种高致死率的癌症,主要原因是诊断较晚、肿瘤异质性和致密的免疫抑制间质限制了治疗效果。虽然像FOLFIRINOX和基于吉西他滨的治疗方案提供了一些好处,但治疗选择仍然是经验主义的,没有可靠的预测模型来指导个性化的决策。我们采用了先前验证的血清衍生的教育球体技术,使用PDAC患者血清创建3D球体。这些球体在8天的时间里保持了结构的完整性、活力和一致的大小,避免了过度生长。它们还表现出细胞外基质沉积,如I型胶原蛋白,并表达参与耐药和肿瘤进展的关键基因,包括COL1A1、FN1、MMP2、CXCL1和CXCL2。使用目标非依赖性细胞杀伤(TICK)策略,我们建立了个性化的化疗图来评估真正的治疗反应,帮助临床医生完善最佳治疗方案。在一项16例研究中,我们的模型与吉西他滨、Gem-Pac和FOLFIRINOX治疗的临床反应高度一致,支持其在个性化护理中的应用。最后,我们证明,在治疗开始前的短时间内收集患者血清时,预测准确性最高。这些发现支持PDAC患者血清教育球体作为一种快速、无创和生理相关的工具,用于指导个性化化疗和实时监测治疗反应。
{"title":"A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma","authors":"Sara Cherradi ,&nbsp;Salomé Roux ,&nbsp;Marie Dupuy ,&nbsp;Eric Assenat ,&nbsp;Hong Tuan Duong","doi":"10.1016/j.tranon.2025.102659","DOIUrl":"10.1016/j.tranon.2025.102659","url":null,"abstract":"<div><div>Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer, largely due to late diagnosis, tumor heterogeneity, and a dense, immunosuppressive stroma that limits therapeutic efficacy. While regimens like FOLFIRINOX and gemcitabine-based therapies offer some benefit, treatment selection remains empirical, with no reliable predictive models to guide personalized decisions. We adapted our previously validated serum-derived educated spheroid technology creating 3D spheroids using PDAC patient serum. These spheroids maintained structural integrity, viability, and consistent size over eight days, avoiding overgrowth. They also exhibited extracellular matrix deposition such as type I collagen, and expressed key genes involved in drug resistance and tumor progression including <em>COL1A1, FN1, MMP2, CXCL1</em>, and <em>CXCL2</em>. Using the Target-Independent Cell Killing (TICK) strategy, we established individualized chemograms to assess true therapeutic response helping clinicians in refining the optimal treatment protocol. In a 16-case study, our model achieved high concordance with clinical responses across gemcitabine, Gem-Pac, and FOLFIRINOX treatments supporting its utility in personalized care. Finally, we demonstrated that predictive accuracy was highest when patient serum was collected within a short window prior to treatment initiation. These findings support PDAC patient serum-educated spheroids as a rapid, non-invasive, and physiologically relevant tool for guiding personalized chemotherapy and monitoring treatment response in real time.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102659"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway maz介导的泛素偶联酶E2C上调通过MAPK信号通路促进乳腺癌进展。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102646
Jinhui Bai , Mei Deng , Xueting Wu , Chao Xiong , Huixian Wu , Li Wang , Jie Qin

Background

Malignant proliferation and invasion of tumor cells are the primary causes of death among patients with breast cancer, yet the molecular mechanisms orchestrating cancer metastasis are not well elucidated. Ubiquitin-conjugating enzyme E2C (UBE2C) has been reported to be involved in the tumorigenesis and development of various malignant tumors; however, the biological roles and underlying mechanisms of UBE2C in breast cancer remain unclear.

Methods

UBE2C expression was analyzed in breast cancer tissue and cell lines using immunohistochemistry, quantitative reverse transcription PCR (RT-qPCR) and Western blot. The biological roles of UBE2C and its transcription factor MAZ were investigated in vitro using CCK-8, plate cloning, scratch, Transwell, cell cycle and apoptosis assays, while a nude mouse subcutaneous tumorigenic model was employed for the in vivo studies. Dual-luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were conducted to validate the binding relationship between MAZ and UBE2C.

Results

UBE2C expression is elevated in breast cancer, and higher levels of UBE2C are associated with poorer survival among patients with breast cancer. UBE2C promotes the progression of breast cancer both in vivo and in vitro. Additionally, UBE2C is a direct transcriptional target of MAZ, which also accelerates malignant development of breast cancer. Furthermore, UBE2C exerts its oncogenic effects dependent on the MAPK signaling pathway.

Conclusion

Our findings highlight the critical role of the MAZ/UBE2C/MAPK signaling axis in the progression of breast cancer and identify potential novel therapeutic targets for its treatment.
背景:肿瘤细胞的恶性增殖和侵袭是乳腺癌患者死亡的主要原因,但调控肿瘤转移的分子机制尚不清楚。据报道,泛素偶联酶E2C (UBE2C)参与多种恶性肿瘤的发生和发展;然而,UBE2C在乳腺癌中的生物学作用和潜在机制尚不清楚。方法:采用免疫组织化学、定量反转录PCR (RT-qPCR)和Western blot技术分析乳腺癌组织和细胞系中UBE2C的表达。采用CCK-8法、平板克隆法、scratch法、Transwell法、细胞周期法和细胞凋亡法研究UBE2C及其转录因子MAZ在体外的生物学作用,并采用裸鼠皮下致瘤模型进行体内研究。通过双荧光素酶报告基因实验和染色质免疫沉淀(ChIP)实验验证MAZ与UBE2C的结合关系。结果:UBE2C在乳腺癌中表达升高,且UBE2C水平升高与乳腺癌患者较差的生存率相关。UBE2C在体内和体外均促进乳腺癌的进展。此外,UBE2C是MAZ的直接转录靶点,也加速了乳腺癌的恶性发展。此外,UBE2C依赖于MAPK信号通路发挥其致癌作用。结论:我们的研究结果强调了MAZ/UBE2C/MAPK信号轴在乳腺癌进展中的关键作用,并确定了潜在的新治疗靶点。
{"title":"MAZ-Mediated ubiquitin-conjugating enzyme E2C upregulation promotes breast cancer progression via the MAPK signaling pathway","authors":"Jinhui Bai ,&nbsp;Mei Deng ,&nbsp;Xueting Wu ,&nbsp;Chao Xiong ,&nbsp;Huixian Wu ,&nbsp;Li Wang ,&nbsp;Jie Qin","doi":"10.1016/j.tranon.2025.102646","DOIUrl":"10.1016/j.tranon.2025.102646","url":null,"abstract":"<div><h3>Background</h3><div>Malignant proliferation and invasion of tumor cells are the primary causes of death among patients with breast cancer, yet the molecular mechanisms orchestrating cancer metastasis are not well elucidated. Ubiquitin-conjugating enzyme E2C (UBE2C) has been reported to be involved in the tumorigenesis and development of various malignant tumors; however, the biological roles and underlying mechanisms of UBE2C in breast cancer remain unclear.</div></div><div><h3>Methods</h3><div>UBE2C expression was analyzed in breast cancer tissue and cell lines using immunohistochemistry, quantitative reverse transcription PCR (RT-qPCR) and Western blot. The biological roles of UBE2C and its transcription factor MAZ were investigated in vitro using CCK-8, plate cloning, scratch, Transwell, cell cycle and apoptosis assays, while a nude mouse subcutaneous tumorigenic model was employed for the in vivo studies. Dual-luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay were conducted to validate the binding relationship between MAZ and UBE2C.</div></div><div><h3>Results</h3><div>UBE2C expression is elevated in breast cancer, and higher levels of UBE2C are associated with poorer survival among patients with breast cancer. UBE2C promotes the progression of breast cancer both in vivo and in vitro. Additionally, UBE2C is a direct transcriptional target of MAZ, which also accelerates malignant development of breast cancer. Furthermore, UBE2C exerts its oncogenic effects dependent on the MAPK signaling pathway.</div></div><div><h3>Conclusion</h3><div>Our findings highlight the critical role of the MAZ/UBE2C/MAPK signaling axis in the progression of breast cancer and identify potential novel therapeutic targets for its treatment.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102646"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell analysis identifies a stemness-associated tumor cell subpopulation and develops a prognostic scoring model in esophageal squamous cell carcinoma 单细胞分析确定了一个干细胞相关的肿瘤细胞亚群,并在食管鳞状细胞癌中建立了一个预后评分模型。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102653
Wei Ye , Wei Su , Chang Lei , Chenjun Huang , Mingjun Du
Esophageal squamous cell carcinoma (ESCC) exhibits marked heterogeneity and poor prognosis, but the contribution of stemness‑related tumor cells remains unclear. Using single‑cell RNA sequencing, we identified eight tumor subpopulations in ESCC, among which one cluster displayed prominent stem‑like and proliferative features with high expression of MKI67, STMN1, and UBE2C. Based on its marker genes, we established a stemness‑associated scoring model (SASM). Validation in independent TCGA and GSE53624 cohorts confirmed that higher SASM scores predicted shorter overall survival and reduced immune infiltration, particularly of CD8⁺ T cells. SASM scores were positively correlated with tumor mutational burden (TMB), and patients with high SASM and low TMB exhibited the poorest outcomes. Further analysis identified TFDP1 as a key gene associated with SASM and adverse prognosis, which was upregulated in tumor tissues and promoted ESCC cell proliferation in vitro. Overall, our study delineates stemness‑related tumor heterogeneity in ESCC, proposes a prognostic scoring system with immunological relevance, and highlights TFDP1 as a potential therapeutic target.
食管鳞状细胞癌(ESCC)具有明显的异质性和较差的预后,但与干性相关的肿瘤细胞的作用尚不清楚。通过单细胞RNA测序,我们在ESCC中鉴定出8个肿瘤亚群,其中一个亚群表现出突出的干细胞样和增殖特征,MKI67、STMN1和UBE2C高表达。基于其标记基因,我们建立了茎干相关评分模型(SASM)。在独立的TCGA和GSE53624队列中的验证证实,较高的SASM评分预示着更短的总生存期和更少的免疫浸润,尤其是CD8 + T细胞。SASM评分与肿瘤突变负荷(TMB)呈正相关,SASM高、TMB低的患者预后最差。进一步分析发现TFDP1是与SASM及不良预后相关的关键基因,在肿瘤组织中表达上调,促进体外ESCC细胞增殖。总的来说,我们的研究描述了ESCC中与干细胞相关的肿瘤异质性,提出了一种具有免疫学相关性的预后评分系统,并强调了TFDP1是一个潜在的治疗靶点。
{"title":"Single-cell analysis identifies a stemness-associated tumor cell subpopulation and develops a prognostic scoring model in esophageal squamous cell carcinoma","authors":"Wei Ye ,&nbsp;Wei Su ,&nbsp;Chang Lei ,&nbsp;Chenjun Huang ,&nbsp;Mingjun Du","doi":"10.1016/j.tranon.2025.102653","DOIUrl":"10.1016/j.tranon.2025.102653","url":null,"abstract":"<div><div>Esophageal squamous cell carcinoma (ESCC) exhibits marked heterogeneity and poor prognosis, but the contribution of stemness‑related tumor cells remains unclear. Using single‑cell RNA sequencing, we identified eight tumor subpopulations in ESCC, among which one cluster displayed prominent stem‑like and proliferative features with high expression of MKI67, STMN1, and UBE2C. Based on its marker genes, we established a stemness‑associated scoring model (SASM). Validation in independent TCGA and GSE53624 cohorts confirmed that higher SASM scores predicted shorter overall survival and reduced immune infiltration, particularly of CD8⁺ T cells. SASM scores were positively correlated with tumor mutational burden (TMB), and patients with high SASM and low TMB exhibited the poorest outcomes. Further analysis identified TFDP1 as a key gene associated with SASM and adverse prognosis, which was upregulated in tumor tissues and promoted ESCC cell proliferation in vitro. Overall, our study delineates stemness‑related tumor heterogeneity in ESCC, proposes a prognostic scoring system with immunological relevance, and highlights TFDP1 as a potential therapeutic target.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102653"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment 围手术期非小细胞肺癌的适应性治疗:以动态最小残留疾病调整为指导的策略。
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102660
Li-Jin Xie , Li-Li Fu , Shu-Cen Liu , Chang-Sen Bai , Bai-Cheng Xu , Xiong-Wen He , Hai-Feng Lin , Yue-Can Zeng , Wen-Jun Tang
Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the “Four-Dimensional TNMB Staging System,” which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification.
Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of “monitoring-intervention-remonitoring,” establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.
肺癌仍然是全球癌症发病率和死亡率的主要原因,非小细胞肺癌(NSCLC)约占85%。低早期诊断率和高隐匿性转移率限制了常规治疗的生存效益。目前的TNM分期体系未能充分反映肿瘤的异质性和疾病的动态分子演化,影响了复发的预测和预后分层。最近在微小残留病变(MRD)检测方面的一些进展,如超灵敏液体活检技术,在很大程度上克服了传统成像的局限性,并为肺癌的连续、精确管理提供了一种变革性的方法。本文系统总结了MRD检测技术的发展,并强调了其在指导非小细胞肺癌适应性治疗方面的临床意义,包括治疗升级、降级和精确引导药物假期的新概念。此外,作者全面讨论了“四维TNMB分期系统”,该系统结合了连续的分子监测,以解决传统分期的静态局限性,提高预后分层的准确性。尽管存在诸如缺乏标准化解释标准和检测灵敏度有限等挑战,但与第三代液体活检平台、多组学分析和多中心前瞻性验证研究相结合,有望推进mrd指导策略的临床实施。范式的转变将使非小细胞肺癌的管理从传统的标准化模式过渡到“监测-干预-再监测”的精确指导闭环系统,为全面的、分子驱动的管理策略奠定坚实的理论和实践基础。
{"title":"Adaptive therapy for perioperative non–small cell lung cancer: strategies guided by dynamic minimal residual disease adjustment","authors":"Li-Jin Xie ,&nbsp;Li-Li Fu ,&nbsp;Shu-Cen Liu ,&nbsp;Chang-Sen Bai ,&nbsp;Bai-Cheng Xu ,&nbsp;Xiong-Wen He ,&nbsp;Hai-Feng Lin ,&nbsp;Yue-Can Zeng ,&nbsp;Wen-Jun Tang","doi":"10.1016/j.tranon.2025.102660","DOIUrl":"10.1016/j.tranon.2025.102660","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer incidence and mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for about 85% of cases. The low rate of early diagnosis and the high rate of occult metastases limit the survival benefits of conventional treatments. The current TNM staging system fails to fully reflect tumor heterogeneity or the dynamic molecular evolution of the disease, thus affecting the prediction of recurrence and the prognostic stratification. Some recent advances in minimal residual disease (MRD) detection, such as ultra-sensitive liquid biopsy technologies, have largely overcome the limitations of traditional imaging and offered a transformative approach for continuous, precision-based management of lung cancer. This review systematically summarized the technological evolution of MRD detection and highlighted its clinical significance in guiding adaptive therapy for NSCLC, including treatment escalation, de-escalation, and the emerging concept of precision-guided drug holidays. Moreover, the authors comprehensively discussed the “Four-Dimensional TNMB Staging System,” which incorporates continuous molecular monitoring to address the static limitations of conventional staging and enhance the accuracy of prognostic stratification.</div><div>Although ongoing challenges, such as the lack of standardized interpretation criteria and limited detection sensitivity, the combinations with the third-generation liquid biopsy platforms, multi-omics analyses, and multi-center prospective validation studies are expected to advance the clinical implementation of MRD-guided strategies. The paradigm change will enable the transition of NSCLC management from conventional standardized models to a precision-guided, closed-loop system of “monitoring-intervention-remonitoring,” establishing a solid theoretical and practical foundation for comprehensive, molecularly driven management strategies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102660"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management CAR-T治疗非小细胞肺癌:心脏毒性管理的临床前景、潜力和策略
IF 5 2区 医学 Q2 Medicine Pub Date : 2026-01-06 DOI: 10.1016/j.tranon.2025.102662
Yihao Liu , Yizhu Gao , Chenyu Huo , Tao Zeng , Wenjun Meng , Haoling Zhang , Qinqin He
Lung cancer ranks first among all malignancies in incidence, with current treatment strategies including surgery, chemotherapy, immunotherapy, and targeted therapy. Despite these advances, drug resistance in advanced non-small cell lung cancer (NSCLC) remains a major obstacle and innovative therapeutic approaches are imperative to address it. Chimeric antigen receptor T-cell (CAR-T) therapy has shown impressive and long-lasting results in blood cancers, but its success in solid tumors such as lung cancer remains limited. This review summarizes recent advances and future directions of CAR-T therapy in NSCLC, focusing on major therapeutic targets such as EGFR, MSLN, PD-L1, MUC1, CEA, and ROR1, as well as on the efficacy and potential of combining CAR-T therapy with other treatment modalities. Additionally, we discuss adverse events in NSCLC patients undergoing CAR-T therapy, emphasizing cytokine release syndrome (CRS) and cardiovascular complications—their incidence, pathophysiology, interrelation, and management strategies.
肺癌在所有恶性肿瘤中发病率居首位,目前的治疗策略包括手术、化疗、免疫治疗和靶向治疗。尽管取得了这些进展,但晚期非小细胞肺癌(NSCLC)的耐药性仍然是一个主要障碍,需要创新的治疗方法来解决这一问题。嵌合抗原受体t细胞(CAR-T)疗法在血癌中显示出令人印象深刻和持久的效果,但它在肺癌等实体肿瘤中的成功仍然有限。本文综述了CAR-T治疗NSCLC的最新进展和未来发展方向,重点介绍了EGFR、MSLN、PD-L1、MUC1、CEA、ROR1等主要治疗靶点,以及CAR-T联合其他治疗方式的疗效和潜力。此外,我们还讨论了接受CAR-T治疗的非小细胞肺癌患者的不良事件,强调细胞因子释放综合征(CRS)和心血管并发症——它们的发生率、病理生理学、相互关系和管理策略。
{"title":"CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management","authors":"Yihao Liu ,&nbsp;Yizhu Gao ,&nbsp;Chenyu Huo ,&nbsp;Tao Zeng ,&nbsp;Wenjun Meng ,&nbsp;Haoling Zhang ,&nbsp;Qinqin He","doi":"10.1016/j.tranon.2025.102662","DOIUrl":"10.1016/j.tranon.2025.102662","url":null,"abstract":"<div><div>Lung cancer ranks first among all malignancies in incidence, with current treatment strategies including surgery, chemotherapy, immunotherapy, and targeted therapy. Despite these advances, drug resistance in advanced non-small cell lung cancer (NSCLC) remains a major obstacle and innovative therapeutic approaches are imperative to address it. Chimeric antigen receptor T-cell (CAR-T) therapy has shown impressive and long-lasting results in blood cancers, but its success in solid tumors such as lung cancer remains limited. This review summarizes recent advances and future directions of CAR-T therapy in NSCLC, focusing on major therapeutic targets such as EGFR, MSLN, PD-L1, MUC1, CEA, and ROR1, as well as on the efficacy and potential of combining CAR-T therapy with other treatment modalities. Additionally, we discuss adverse events in NSCLC patients undergoing CAR-T therapy, emphasizing cytokine release syndrome (CRS) and cardiovascular complications—their incidence, pathophysiology, interrelation, and management strategies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102662"},"PeriodicalIF":5.0,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “A Clinical Study on the Efficacy of Concurrent Chemoradiotherapy Combined with Targeted Therapy and Hyperthermia in Patients with Locally Advanced Cervical Cancer” [Translational Oncology,Volume61, November 2025, 102516] “同步放化疗联合靶向治疗和热疗治疗局部晚期宫颈癌疗效的临床研究”的勘误表[转化肿瘤学,vol . 61,十一月2025,102516]
IF 5 2区 医学 Q2 Medicine Pub Date : 2025-12-30 DOI: 10.1016/j.tranon.2025.102656
Yuhan Jia , Feng Zhang , Kun Zou , Lijuan Zou
{"title":"Corrigendum to “A Clinical Study on the Efficacy of Concurrent Chemoradiotherapy Combined with Targeted Therapy and Hyperthermia in Patients with Locally Advanced Cervical Cancer” [Translational Oncology,Volume61, November 2025, 102516]","authors":"Yuhan Jia ,&nbsp;Feng Zhang ,&nbsp;Kun Zou ,&nbsp;Lijuan Zou","doi":"10.1016/j.tranon.2025.102656","DOIUrl":"10.1016/j.tranon.2025.102656","url":null,"abstract":"","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102656"},"PeriodicalIF":5.0,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The HYAL1 paradox in cancer: From complex tumor biology to novel therapeutic strategies 癌症中的HYAL1悖论:从复杂的肿瘤生物学到新的治疗策略
IF 5 2区 医学 Q2 Medicine Pub Date : 2025-12-19 DOI: 10.1016/j.tranon.2025.102649
Yun Jin, Tongyu Wang, Junyan Ma, Jiao Quan, Ning Zhou
Hyaluronidase 1 (HYAL1), a key enzyme in hyaluronic acid (HA) metabolism, exhibits a perplexing paradoxical character in tumor biology. This review systematically delineates the dual roles of HYAL1 in cancer: on one hand, by degrading HA to generate low-molecular-weight fragments with pro-angiogenic and immunomodulatory activities, HYAL1 promotes tumor progression and metastasis in various malignancies, including prostate cancer, esophageal carcinoma, and osteosarcoma; on the other hand, it demonstrates tumor-suppressive properties in specific contexts such as colorectal cancer models. This functional contradiction underscores the context-dependent nature of HYAL1, whose activity and effects are profoundly influenced by tumor type, microenvironmental features, and epigenetic regulation.
Mechanistically, HYAL1 functions not only through the classical HA-CD44 signaling axis but also by regulating the MMPs/TIMPs balance, integrin activation, and cytoskeletal reorganization. Recent studies reveal that HYAL1 expression is directly controlled by epigenetic regulators like BRD2, while its activity can be monitored in real-time using novel bioluminescent probes, providing powerful tools for investigating its dynamic functions. Notably, HYAL1-based therapeutic strategies have shown considerable promise, particularly in oncolytic virotherapy, where HYAL1-expressing recombinant viruses significantly enhance the penetration and efficacy of chemotherapeutic agents and immune cells within tumors.
Key challenges persist, including HA metabolic complexity, functional redundancy among hyaluronidases, and HA fragment instability. Future research must decipher HYAL1′s context-specific roles within tumor heterogeneity, elucidate its epigenetic regulation, and develop targeted strategies. A deeper understanding of this HYAL1 paradox is essential to leverage its potential for precision cancer therapies targeting HA metabolism.
透明质酸酶1 (HYAL1)是透明质酸(HA)代谢的关键酶,在肿瘤生物学中表现出令人困惑的矛盾特征。本综述系统地描述了HYAL1在癌症中的双重作用:一方面,通过降解透明质酸生成具有促血管生成和免疫调节活性的低分子量片段,HYAL1促进各种恶性肿瘤的肿瘤进展和转移,包括前列腺癌、食管癌和骨肉瘤;另一方面,它在特定情况下如结直肠癌模型中显示出肿瘤抑制特性。这种功能矛盾强调了HYAL1的环境依赖性,其活性和作用受到肿瘤类型、微环境特征和表观遗传调控的深刻影响。从机制上讲,HYAL1不仅通过经典的HA-CD44信号轴发挥作用,还通过调节MMPs/TIMPs平衡、整合素激活和细胞骨架重组发挥作用。最近的研究表明,HYAL1的表达受BRD2等表观遗传调控因子的直接控制,而利用新型生物发光探针可以实时监测其活性,为研究其动态功能提供了有力的工具。值得注意的是,基于hyal1的治疗策略已经显示出相当大的前景,特别是在溶瘤病毒治疗中,表达hyal1的重组病毒显著提高了化疗药物和肿瘤内免疫细胞的渗透和功效。关键的挑战仍然存在,包括透明质酸代谢的复杂性,透明质酸酶之间的功能冗余,以及HA片段的不稳定性。未来的研究必须破译HYAL1在肿瘤异质性中的环境特异性作用,阐明其表观遗传调控,并制定有针对性的策略。更深入地了解这种HYAL1悖论对于利用其针对血凝素代谢的精确癌症治疗的潜力至关重要。
{"title":"The HYAL1 paradox in cancer: From complex tumor biology to novel therapeutic strategies","authors":"Yun Jin,&nbsp;Tongyu Wang,&nbsp;Junyan Ma,&nbsp;Jiao Quan,&nbsp;Ning Zhou","doi":"10.1016/j.tranon.2025.102649","DOIUrl":"10.1016/j.tranon.2025.102649","url":null,"abstract":"<div><div>Hyaluronidase 1 (HYAL1), a key enzyme in hyaluronic acid (HA) metabolism, exhibits a perplexing paradoxical character in tumor biology. This review systematically delineates the dual roles of HYAL1 in cancer: on one hand, by degrading HA to generate low-molecular-weight fragments with pro-angiogenic and immunomodulatory activities, HYAL1 promotes tumor progression and metastasis in various malignancies, including prostate cancer, esophageal carcinoma, and osteosarcoma; on the other hand, it demonstrates tumor-suppressive properties in specific contexts such as colorectal cancer models. This functional contradiction underscores the context-dependent nature of HYAL1, whose activity and effects are profoundly influenced by tumor type, microenvironmental features, and epigenetic regulation.</div><div>Mechanistically, HYAL1 functions not only through the classical HA-CD44 signaling axis but also by regulating the MMPs/TIMPs balance, integrin activation, and cytoskeletal reorganization. Recent studies reveal that HYAL1 expression is directly controlled by epigenetic regulators like BRD2, while its activity can be monitored in real-time using novel bioluminescent probes, providing powerful tools for investigating its dynamic functions. Notably, HYAL1-based therapeutic strategies have shown considerable promise, particularly in oncolytic virotherapy, where HYAL1-expressing recombinant viruses significantly enhance the penetration and efficacy of chemotherapeutic agents and immune cells within tumors.</div><div>Key challenges persist, including HA metabolic complexity, functional redundancy among hyaluronidases, and HA fragment instability. Future research must decipher HYAL1′s context-specific roles within tumor heterogeneity, elucidate its epigenetic regulation, and develop targeted strategies. A deeper understanding of this HYAL1 paradox is essential to leverage its potential for precision cancer therapies targeting HA metabolism.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102649"},"PeriodicalIF":5.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BioMarrow: An accessible and reproducible 3D patient-derived bone marrow model for advancing research and clinical applications BioMarrow:一种可获取且可复制的3D患者骨髓模型,用于推进研究和临床应用
IF 5 2区 医学 Q2 Medicine Pub Date : 2025-12-19 DOI: 10.1016/j.tranon.2025.102643
Diana Lourenço , Raquel Lopes , Joana Caetano , Filipa Barahona , Jessica Rodrigues , Ana C. Queirós , Emilie Arnault Carneiro , Cristina João
Preclinical models for multiple myeloma (MM) often fail to recapitulate the complexity of the bone marrow (BM) microenvironment, limiting their utility for drug testing and translational research. There is an urgent need for physiologically relevant, patient-adaptable platforms to support personalized therapeutic evaluation.
We developed BioMarrow, a 3D ex vivo BM culture system using unmanipulated patient BM aspirates embedded in Matrigel. Culture conditions were optimized to sustain diverse hematopoietic, stromal and immune populations for up to 7 days. Spatial distribution, cytokine secretion and treatment responses were assessed via flow cytometry, immunohistochemistry, multiplex ELISA and cell viability assays.
The model maintained key BM components characteristics of MM, supported stromal network formation and preserved cytokines such as IL-6 and TGF-β. Immune-effector cytokines were reduced, consistent with a tumour-permissive microenvironment. Drug testing with MM cell lines confirmed BioMarrow's ability to discriminate treatment sensitivity.
BioMarrow captures essential features of the MM niche and offers a clinically relevant, short-term platform for ex vivo therapeutic screening. Its scalability and immune component preservation support future integration into personalized treatment workflows, including immunotherapy evaluation.
多发性骨髓瘤(MM)的临床前模型往往不能概括骨髓(BM)微环境的复杂性,限制了它们在药物测试和转化研究中的应用。迫切需要生理学相关的、患者适应性强的平台来支持个性化的治疗评估。我们开发了BioMarrow,这是一种3D离体BM培养系统,使用未操作的患者BM吸管嵌入Matrigel。对培养条件进行优化,以维持多种造血、基质和免疫群体长达7天。通过流式细胞术、免疫组织化学、多重ELISA和细胞活力测定来评估空间分布、细胞因子分泌和治疗反应。该模型维持了MM的关键BM成分特征,支持基质网络的形成,并保留了IL-6和TGF-β等细胞因子。免疫效应细胞因子减少,与肿瘤容许微环境一致。MM细胞系的药物测试证实了BioMarrow区分治疗敏感性的能力。BioMarrow抓住了MM利基的基本特征,并为体外治疗筛选提供了临床相关的短期平台。其可扩展性和免疫成分保存支持未来集成到个性化治疗工作流程,包括免疫治疗评估。
{"title":"BioMarrow: An accessible and reproducible 3D patient-derived bone marrow model for advancing research and clinical applications","authors":"Diana Lourenço ,&nbsp;Raquel Lopes ,&nbsp;Joana Caetano ,&nbsp;Filipa Barahona ,&nbsp;Jessica Rodrigues ,&nbsp;Ana C. Queirós ,&nbsp;Emilie Arnault Carneiro ,&nbsp;Cristina João","doi":"10.1016/j.tranon.2025.102643","DOIUrl":"10.1016/j.tranon.2025.102643","url":null,"abstract":"<div><div>Preclinical models for multiple myeloma (MM) often fail to recapitulate the complexity of the bone marrow (BM) microenvironment, limiting their utility for drug testing and translational research. There is an urgent need for physiologically relevant, patient-adaptable platforms to support personalized therapeutic evaluation.</div><div>We developed BioMarrow, a 3D <em>ex vivo</em> BM culture system using unmanipulated patient BM aspirates embedded in Matrigel. Culture conditions were optimized to sustain diverse hematopoietic, stromal and immune populations for up to 7 days. Spatial distribution, cytokine secretion and treatment responses were assessed via flow cytometry, immunohistochemistry, multiplex ELISA and cell viability assays.</div><div>The model maintained key BM components characteristics of MM, supported stromal network formation and preserved cytokines such as IL-6 and TGF-β. Immune-effector cytokines were reduced, consistent with a tumour-permissive microenvironment. Drug testing with MM cell lines confirmed BioMarrow's ability to discriminate treatment sensitivity.</div><div>BioMarrow captures essential features of the MM niche and offers a clinically relevant, short-term platform for <em>ex vivo</em> therapeutic screening. Its scalability and immune component preservation support future integration into personalized treatment workflows, including immunotherapy evaluation.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"64 ","pages":"Article 102643"},"PeriodicalIF":5.0,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145798221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1